Robinson Dean M, Wellington Keri
Adis International Limited, Auckland, New Zealand.
Drugs. 2006;66(2):257-71. doi: 10.2165/00003495-200666020-00011.
A low-dose sustained-release (SR) formulation of the thiazide-type diuretic indapamide, indapamide SR (Natrilix SR), retains the antihypertensive activity of the immediate-release (IR) formulation, with a smoother pharmacokinetic profile. In well controlled 12- to 52-week clinical trials, indapamide SR 1.5 mg/day was well tolerated and reduced blood pressure as effectively as therapeutic dosages of amlodipine, candesartan, enalapril, hydrochlorothiazide or indapamide IR. Indapamide SR was also more effective than enalapril in reducing left ventricular hypertrophy (LVH), and similar reductions in renal end-organ damage, assessed by microalbuminuria, were seen with indapamide SR- and enalapril-based antihypertensive strategies. Indapamide SR provides an effective option for initial antihypertensive monotherapy and a basis for multidrug antihypertensive strategies.
噻嗪类利尿剂吲达帕胺的低剂量缓释（SR）制剂，即吲达帕胺缓释片（纳催离缓释片），保留了速释（IR）制剂的降压活性，且药代动力学特征更平稳。在为期12至52周的严格对照临床试验中，吲达帕胺缓释片1.5毫克/天耐受性良好，降压效果与氨氯地平、坎地沙坦、依那普利、氢氯噻嗪或吲达帕胺速释制剂的治疗剂量相当。在减轻左心室肥厚（LVH）方面，吲达帕胺缓释片也比依那普利更有效，通过微量白蛋白尿评估，基于吲达帕胺缓释片和依那普利的降压策略在减轻肾脏终末器官损害方面效果相似。吲达帕胺缓释片为初始抗高血压单药治疗提供了一种有效的选择，也是多药联合抗高血压策略的基础。
